Healthcare and biotech keep throwing up startups that go after problems the big players have left alone. Here are three UK ones I’ve been reading about, each at a different stage of the care and drug pipeline. Has anyone come across them?
-
Ignota Labs: giving failed drugs a second chance
Ignota Labs is a Cambridge-based startup, founded in 2021 by Layla Hosseini-Gerami, Sam Windsor and Jordan Lane. It focuses on drugs that were abandoned because of safety concerns, often when they were 80-90% of the way through development. Its AI platform, SAFEPATH, combines deep learning, cheminformatics and bioinformatics to work out why a compound causes toxicity, so it can be redesigned. The company says more than half of clinical trial failures come down to safety, which is the gap it targets. It closed a $6.9M (£5.5M) seed round in February 2025, co-led by Montage Ventures and AIX Ventures, and is moving its first asset, a PDE9A inhibitor, towards early clinical trials. -
LinkGevity: targeting necrosis in age-related disease
LinkGevity was founded by sisters Dr Carina Kern and Serena Kern-Libera and is based at the Babraham Research Campus near Cambridge. Its lead drug is a small molecule designed to block necrosis, the uncontrolled death of cells linked to a range of age-related conditions, with kidney disease as the planned entry point. It has won an Innovate UK Smart Grant and a Horizon Europe grant, and was selected for the KQ Labs programme at the Francis Crick Institute. Human trials depend on regulatory approval, and analysts put the global longevity market at around £25bn. -
Medwise AI: faster answers at the point of care
Medwise ai is a Leeds-based health tech company, founded by Dr Keith Tsui and Luis Ulloa. Its AI-powered search tool lets clinicians ask a question and get a concise answer drawn from UK guidelines, and for organisations it can also search local NHS policies and pathways. It is DTAC certified, which helps NHS procurement, and won an Innovate UK Smart Grant in 2022. The company says each search saves about 2.6 minutes, which is its own figure, so independent evidence will be worth watching.
The common thread
Each one tackles a bottleneck rather than a headline disease: wasted drug candidates, the biology of ageing, and the time clinicians lose hunting for guidance.
Questions for the thread:
Is rescuing abandoned drugs a smarter bet than discovering new ones?
Can ageing be treated as a drug target, or is that still too early to call?
Would you trust an AI search tool for clinical questions, and what would it need to prove first?
Looking forward to your thoughts.